Medication info
SitaPlus Sustained Release Tablet 100/1000 mg (Sitagliptin, Metformin)

SitaPlus Sustained Release Tablet 100/1000 mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.37mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Bright blue, biconvex, oval-shaped sustained release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202301868 · Approved 2023.06.20 · Insurance code 648604580

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, this medicine must be swallowed without splitting, crushing, grinding, or chewing. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine as a 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in patients with type 2 diabetes who are using sitagliptin and metformin together, to help improve blood sugar control more effectively along with dietary and exercise therapy.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with food once daily, preferably in the evening, and the dose should be increased gradually. To maintain the extended-release properties, this medicine must be swallowed without splitting, crushing, grinding, or chewing. Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine as a 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose is not adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If blood glucose is not adequately controlled with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: - The recommended initial total daily dose of this medicine for patients whose blood glucose is not adequately controlled with metformin monotherapy is sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously taking immediate-release metformin at a dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg per day. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains sitagliptin and metformin for diabetes treatment, and there are several important precautions when taking it. First, the sitagliptin component can, although rarely, cause serious allergic reactions, so if symptoms such as rash, difficulty breathing, or swelling of the face or neck occur, it is necessary to stop taking the medication immediately and seek medical attention. Second, there is a risk of pancreatitis, which is inflammation of the pancreas, so if sudden abdominal pain, vomiting, or nausea occurs after taking the medication, medical personnel should be notified immediately. Third, the metformin component can rarely cause a serious metabolic disorder called lactic acidosis, which is a very dangerous condition. Therefore, if symptoms such as difficulty breathing, muscle pain, fatigue, or abdominal pain occur, one must go to the hospital immediately. Additionally, this medication should not be administered to patients with moderate to severe renal impairment, severe infections or dehydration, heart failure, acute myocardial infarction, or acute illnesses affecting renal function. When undergoing tests with radiocontrast agents, it is necessary to discontinue the medication for a certain period before and after the test due to risks of kidney damage and lactic acidosis. It is also safe not to administer this medication to pregnant women or nursing mothers. When taking this medication, special caution should be exercised for irregular meals, excessive exercise, interactions with other medications, and if allergic to the red dye No. 40 contained in this medication. While taking this medication, gastrointestinal disturbances, hypoglycemia, and skin rashes may occur; if symptoms persist or worsen, it is important to consult with medical personnel. Finally, it is advised to temporarily discontinue the medication before and after surgery, during severe infections, or in cases of malnutrition, and to start taking it again once the condition stabilizes.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This helps to safely maintain the effectiveness of the medication for a long time.

Appearance and packaging

Appearance

Bright blue, biconvex, oval-shaped sustained release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.